Ignite Creation Date:
2025-12-24 @ 3:45 PM
Ignite Modification Date:
2025-12-25 @ 1:53 PM
Study NCT ID:
NCT03786692
Status:
RECRUITING
Last Update Posted:
2025-04-16
First Post:
2018-12-21
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Sponsor:
Fox Chase Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-09-04
Start Date Type:
ACTUAL
Primary Completion Date:
2026-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-01
Completion Date Type:
ESTIMATED
First Submit Date:
2018-12-21
First Submit QC Date:
None
Study First Post Date:
2018-12-26
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-04-15
Last Update Post Date:
2025-04-16
Last Update Post Date Type:
ACTUAL